<unk>  may inhibit the metabolism of vitamin K anticoagulants, certain anticonvulsants, and some antidepressants (tricyclic antidepressants, and selective serotonin reuptake inhibitors). Concomitant administration may require dose adjustments, possibly assisted by monitoring of plasma drug concentrations. There are several case reports of<unk>  inducing serotonin syndrome with concomitant administration of antidepressants. When<unk>  is coingested with ethanol, a metabolite called<unk>  is formed via hepatic transesterification, not unlike the hepatic formation of cocaethylene from cocaine and ethanol. The reduced potency of<unk>  and its minor formation means it does not contribute to the pharmacological profile at therapeutic doses and even in overdose cases<unk>  concentrations remain negligible. Coingestion of alcohol (ethanol) also increases the blood plasma levels of d-methylphenidate by up to 40%. Liver toxicity from<unk>  is extremely rare, but limited evidence suggests that intake of β-adrenergic agonists with<unk>  may increase the risk of liver toxicity.
Methylphenidate
Dexmethylphenidate
Ethylphenidate
Atomoxetine
Guanfacine
Psychotherapy
Imipramine
Fluoxetine